FRFrederik C. Roos

Frederik C. Roos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frederik C. Roos has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial

    by Michael Staehler, Michael Stöckle, Daniel C. Christoph, Arnulf Stenzl, Karin Potthoff, Marc‐Oliver Grimm, Dunja Klein, Johanna Harde, Fabian Brüning, Peter J. Goebell, et al.

    MARC‐2, a prospective, multicenter phase IV trial, aimed to investigate clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of one initial vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) therapy and to identify subgroups benefiting most, based on clinical characteristics and biomarkers. Patients with clear cell mRCC failing one initial VEGFR‐TKI received everolimus until progression or unacceptable toxicity. Primary endpoint was 6‐month progression‐free survival rate (6moPFS). Secondary endpoints were overall response rate (ORR), PFS, overall survival (OS), and safety. Between 2011 and 2015, 63 patients were enrolled. Median age was 65.4 years (range 43.3‐81.1). 6moPFS was 39.3% (95% confidence interval [CI], 27.0‐51.3) overall, 54.4% (95% CI, 35.2‐70.1) vs 23.7% (95% CI, 10.5‐39.9) for patients aged ≥65 vs 25 vs ≤25 kg/m2. A Cox proportional hazards model confirmed a longer PFS for patients aged ≥65 years (hazard ratio [HR] 0.46; 95% CI, 0.26‐0.80) and a longer OS for patients with BMI >25 kg/m2 (HR 0.36; 95% CI, 0.18‐0.71). Median PFS and median OS were 3.8 months (95% CI, 3.2‐6.2) and 16.8 months (95% CI, 14.3‐24.3). ORR was 7.9% and disease control rate was 60.3%. No new safety signals emerged. Most common adverse events were stomatitis (31.7%), fatigue (31.7%), and anemia (30.2%). One patient died from treatment‐related upper gastrointestinal hemorrhage. Everolimus remains a safe and effective treatment option for mRCC patients after one prior VEGFR‐TKI therapy. Patients aged ≥65 years and patients with BMI >25 kg/m2 benefited most.


  • Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis

    by Sebastian Frees, Mohammed M. Kamal, Lisa Knoechlein, Robert Bell, Christopher Ziesel, Andreas Neisius, Christian Thomas, Walburgis Brenner, Wolfgang Jäger, Joachim W. Thüroff, et al.


  • Open Access

    Survival advantage of partial over radical nephrectomy in patients presenting with localized renal cell carcinoma

    by Frederik C Roos, Sandra Steffens, Kerstin Junker, Martin Janssen, Frank Becker, Gerd Wegener, Walburgis Brenner, Julie Steinestel, Thomas J Schnoeller, Mark Schrader, et al.

    Partial nephrectomy (PN) preserves renal function and has become the standard approach for T1a renal cell carcinoma (RCC). However, there is still an ongoing debate as to which patients will actually derive greater benefit from partial than from radical nephrectomy (RN). The aim of this study was to retrospectively evaluate the impact of the type of surgery on overall survival (OS) in patients with localized RCC. Renal surgery was performed in 4326 patients with localized RCC (pT ≤ 3a N/M0) at six German tertiary care centers from 1980 to 2010: RN in 2955 cases (68.3%), elective (ePN) in 1108 (25.6%), and imperative partial nephrectomy (iPN) in 263 (6.1%) cases. The median follow-up for all patients was 63 months. Kaplan-Meier and Cox regression analyses were carried out to identify prognosticators for OS. PN was performed significantly more often than RN in patients presenting with lower tumor stages, higher RCC differentiation, and non-clear cell histology. Accordingly, the calculated 5 (10)-year OS rates were 90.0 (74.6)% for ePN, 83.9 (57.5)% for iPN, and 81.2 (64.7)% for RN (p < 0.001). However, multivariate analysis including age, sex, tumor diameter and differentiation, histological subtype, and the year of surgery showed that ePN compared to RN still qualified as an independent factor for improved OS (HR 0.79, 95% CI 0.66-0.94, p = 0.008). Even allowing for the weaknesses of this retrospective analysis, our multicenter study indicates that in patients with localized RCC, PN appears to be associated with better OS than RN irrespective of age or tumor size.


  • Open Access

    High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor

    by Elke Joeckel, Tobias Haber, Dirk Prawitt, Kerstin Junker, Christian Hampel, Joachim W Thüroff, Frederik C Roos, Walburgis Brenner

    Background: The prognosis for renal cell carcinoma (RCC) is related to a high rate of metastasis, including 30% of bone metastasis. Characteristic for bone tissue is a high concentration of calcium ions. In this study, we show a promoting effect of an enhanced extracellular calcium concentration on mechanisms of bone metastasis via the calcium-sensing receptor (CaSR) and its downstream signaling molecules. Methods: Our analyses were performed using 33 (11/category) matched specimens of normal and tumor tissue and 9 (3/category) primary cells derived from RCC patients of the 3 categories: non-metastasized, metastasized into the lung and metastasized into bones during a five-year period after nephrectomy. Expression of CaSR was determined by RT-PCR, Western blot analyses and flow cytometry, respectively. Cells were treated by calcium and the CaSR inhibitor NPS 2143. Cell migration was measured in a Boyden chamber with calcium (10 μM) as chemotaxin and proliferation by BrdU incorporation. The activity of intracellular signaling mediators was quantified by a phospho-kinase array and Western blot. Results: The expression of CaSR was highest in specimens and cells of patients with bone metastases. Calcium treatment induced an increased migration (19-fold) and proliferation (2.3-fold) exclusively in RCC cells from patients with bone metastases. The CaSR inhibitor NPS 2143 elucidated the role of CaSR on the calcium-dependent effects. After treatment with calcium, the activity of AKT, PLCγ-1, p38α and JNK was clearly enhanced and PTEN expression was almost completely abolished in bone metastasizing RCC cells. Conclusions: Our results indicate a promoting effect of extracellular calcium on cell migration and proliferation of bone metastasizing RCC cells via highly expressed CaSR and its downstream signaling pathways. Consequently, CaSR may be regarded as a new prognostic marker predicting RCC bone metastasis.


  • Oncologic Long-term Outcome of Elective Nephron-sparing Surgery Versus Radical Nephrectomy in Patients With Renal Cell Carcinoma Stage pT1b or Greater in a Matched-pair Cohort

    by Frederik C. Roos, Walburgis Brenner, Melanie Müller, Claudia Schubert, Wolfgang J. Jäger, Joachim W. Thüroff, Christian Hampel


  • Perioperative morbidity and renal function in young and elderly patients undergoing elective nephron‐sparing surgery or radical nephrectomy for renal tumours larger than 4 cm

    by Frederik C. Roos, Walburgis Brenner, Wolfgang Jäger, Claudia Albert, Melanie Müller, Joachim W. Thüroff, Christian Hampel

    Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? The incidence of renal tumours is rising constantly. Patients in the 6th or 7th decade of life are mainly affected. Nephron‐sparing surgery (NSS) has become the gold standard for the treatment of patients presenting with renal tumors ≤4 cm and is recommended for cT1b lesions in experienced centers. Little is known about the functional outcome of elderly patients presenting with renal tumours larger than 4 cm and being treated by NSS in comparison to radical nephrectomy (RN). Here we could show that NSS can be performed safely with considerable perioperative morbidity and a better functional outcome according to renal function without lacking oncological control. OBJECTIVE: To analyse renal function, perioperative morbidity and overall survival (OS) in patients aged 65 years treated by radical nephrectomy (RN) or elective nephron‐sparing surgery (NSS) for renal tumours >4 cm. PATIENTS AND METHODS: From our database, we identified 829 patients with renal tumours >4 cm treated by either RN ( n = 641) or NSS ( n = 188) at our institution between 1981 and 2007. After excluding patients with imperative indication and metastases, we identified retrospectively 81 patients aged 65 years (elderly patients) treated for renal tumours >4 cm. In all, 36 and 33 patients underwent NSS and 45 and 52 patients underwent RN in the young and elderly group, respectively. Preoperative and periodically postoperative serum creatinin values were used to estimate glomerular filtration rate (GFR). Chronic kidney disease (CKD) was defined as GFR 2 . Clinical characteristics, complications and renal function were compared between age groups and surgical approaches, and OS was estimated using the Kaplan–Meier method. RESULTS: The median (range) tumour size in young patients was larger compared with that of elderly patients, i.e. 6 (4.2–14.0) cm vs 5 (4.2–16.0) cm, with P < 0.001 considered to be statistically significant. The complication rates did not differ between the age groups ( P = 0.656) or between NSS and RN in young ( P = 0.095) or elderly patients ( P = 0.277). Chronic kidney disease after RN or NSS occurred in 31.1% and 15.5% for young patients, respectively and in 50.9% and 24.2% in elderly patients, respectively, until last available follow‐up which was obtained after a median (range) of 5.69 (0.1–19.2) years for young patients and 5.48 (0.8–18.1) years for elderly patients. Overall survival did not significantly differ between NSS vs RN in young ( P = 0.655) and elderly patients ( P = 0.058). CONCLUSION: Our findings suggest that performing NSS for tumours >4 cm when feasible in young and carefully selected elderly patients is more beneficial for maintaining long‐term renal function. Regardless of age, patients undergoing RN for renal tumours >4 cm developed more new onsets of CKD than patients treated by elective NSS. The complication rate did not differ between the age groups or between types of surgery.


  • Open Access

    Adhesion of renal carcinoma cells to endothelial cells depends on PKCμ

    by Walburgis Brenner, Silke Beitz, Elke Schneider, Frank Benzing, Ronald E Unger, Frederik C Roos, Joachim W Thüroff, Christian Hampel

    The formation of metastases includes the separation of tumor cells from the primary tumor, cell migration into subendothelial tissue and cell proliferation in secondary organ. In this process, cell adhesion of tumor cells to the endothelium is an essential requirement for formation of metastases. Protein kinase C (PKC) regulates adhesion and proliferation. To identify a relation between PKC isoforms and tumor progression in renal cell carcinoma (RCC), the influence of PKC isoforms on cell adhesion and proliferation, and possible influences of integrins were analyzed in RCC cells.


  • Imperative and Elective Indications for Nephron-Sparing Surgery for Renal Tumors: Long-Term Oncological Follow-Up

    by F. Roos, S. Pahernik, W. Brenner, J. Thüroff

    Introduction: Nephron-sparing surgery (NSS) is mandatory for patients with renal tumors in both kidneys or in a solitary kidney in order to preserve renal function (imperative indication). NSS has also become the gold standard (elective indication) for small unilateral renal tumors (< 4 cm) with a normal contralateral kidney. We report the oncological long-term follow-up of NSS of our own series and discuss the results of the current literature. Patients and Methods: From 1979 until 2006, a total of 851 patients was treated at our institu­tion by NSS. The mean tumor diameter was 3 cm (0.5–11 cm) for elective cases and 4.2 cm (1.2–11 cm) for imperative cases. The median follow-up for elective cases is 4.7 years (0.1–24.1 years) and imperative cases 8 years (0.1–25.8 years). Cancer-specific survival (CSS) and local recurrence-free survival (RFS) were estimated. Results: Estimated CSS at 5 and 10 years for elective indications were 98.5 % and 96.7 % and for ­imperative indications (solitary kidney) 89.6 % and 76 %. RFS after 5 and 10 years for elective indications were 98.3 % and 95.7 %; and for imperative indications (solitary kidney) 89.4 % and 79.9 %. Chronic renal failure requiring haemodialysis ­developed after NSS in a solitary kidney in nine patients (11.2 %). Conclusion: NSS can be performed with oncologically safe and good functional results in imperative indications. In elective indications the resectability of a tumour rather than size and location is the limiting factor.


  • Ist die organerhaltende operative Therapie beim Nierenzellkarzinom der Standard?

    by F.C. Roos, W. Brenner, J. W. Thüroff, C. Hampel

  • Open Access

    Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma

    by Frederik C. Roos, Judith Weirich, Anja Victor, Amelie Elsäßer, Walburgis Brenner, Stefan Biesterfeld, Christian Hampel, Joachim W. Thüroff

    OBJECTIVE: To investigate the prognostic relevance of different histopathological features and local tumour extension in patients with pT3b/c N0M0 renal cell carcinoma (RCC), as recently new proposals of reclassifying tumour fat invasion in pT3b/c RCC have been made but the effect of other histopathological tumour characteristics and combinations thereof with tumour invasion has yet to be determined in these patients. PATIENTS AND METHODS: Between 1990 and 2006, 1943 patients underwent surgical treatment for renal tumours in our institution, of which 175 patients (8.7%) had pT3b/c RCC. After exclusion of 57 patients (32.6%) with lymph node and/or distant metastases at the time of diagnosis, 118 (67.4%) remained for retrospective analysis. Different histopathological features and local tumour extension were studied for their association with cancer‐specific‐survival (CSS) and progression‐free‐survival (PFS) by univariate and multivariate analyses. Histopathology was reviewed and revised according to the 2002 Tumour‐Nodes‐Metastasis (TNM) classification system by one pathologist (S.B.). CSS and PFS were estimated by the Kaplan–Meier method. RESULTS: Follow‐up data were obtained from 110 patients at a median (range) of 3.2 (0.3–16.1) years. In univariate analysis, microvascular invasion (MVI) and capsular invasion increased the risk of tumour progression by 2.05‐ and 2.72‐times ( P = 0.037 and P < 0.001). Overall, tumour fat invasion (TFI) and the presence of areas composed by cells with eosinophilic cytoplasm were associated with a higher risk of progression ( P = 0.001 and P = 0.011) and reduced CSS ( P = 0.037 and P = 0.017). In multivariate analysis, MVI and capsular invasion were associated with a two‐fold increased risk of dying from cancer (hazard risk ratio, HR 2.22, P = 0.045 and HR 2.31, P = 0.011). TFI in general ( P = 0.004) and specifically coexistent perirenal fat invasion (PFI) and renal sinus fat invasion (RSFI) were associated with a three‐fold increased risk of developing tumour progression (HR 3.36, P = 0.001). The 10‐year CSS and PFS rates were 39% and 36% for all patients, 47% and 45% for pT3b/c RCC with no PFI or RSFI, and 25% and 10% for PFI + RSFI. CONCLUSION: Patients with pT3b/c RCC with MVI, capsular invasion, TFI and especially PFI + RSFI, have a markedly reduced prognosis compared with patients with pT3b/c RCC without these features. When these results are corroborated by additional studies and external validation, modification of the TNM classification system would be a sensible consequence.